Literature DB >> 30196164

Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.

Laura E Raffals1, Geoffrey C Nguyen2, David T Rubin3.   

Abstract

Entities:  

Year:  2018        PMID： 30196164     DOI： 10.1016/j.cgh.2018.08.064

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  4 in total

Review 1.  Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease.

Authors:  Eman Al Sulais; Turki AlAmeel
Journal:  Biologics       Date:  2020-01-10

Review 2.  Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Authors:  Stefan Schreiber; Shomron Ben-Horin; Rieke Alten; René Westhovens; Laurent Peyrin-Biroulet; Silvio Danese; Toshifumi Hibi; Ken Takeuchi; Fernando Magro; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Walter Reinisch
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 4.070

3.  Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.

Authors:  David M Faleck; Eugenia Shmidt; Ruiqi Huang; Leah G Katta; Neeraj Narula; Rachel Pinotti; Mayte Suarez-Farinas; Jean-Frederic Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2020-06-20       Impact factor: 11.382

4.  The Importance of Countering Biosimilar Disparagement and Misinformation.

Authors:  Hillel P Cohen; Dorothy McCabe
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.